These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 745418)

  • 1. Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p'-DDD for Cushing's syndrome: evidence for the sites of action of the drug.
    Touitou Y; Bogdan A; Luton JP
    J Steroid Biochem; 1978 Dec; 9(12):1217-24. PubMed ID: 745418
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid biosynthesis inhibitors in Cushing's syndrome.
    Engelhardt D
    Clin Investig; 1994 Jul; 72(7):481-8. PubMed ID: 7981573
    [No Abstract]   [Full Text] [Related]  

  • 4. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of o,p'-DDD on adrenal steroidogenesis and hepatic steroid metabolism].
    Ojima M; Saitoh M; Itoh N; Kusano Y; Fukuchi S; Naganuma H
    Nihon Naibunpi Gakkai Zasshi; 1985 Mar; 61(3):168-78. PubMed ID: 3874792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Agents inhibiting steroid biosynthesis--aminoglutethimide and o,p'-DDD].
    Aida M; Miura K
    Nihon Rinsho; 1974 Nov; 32(11):3257-61. PubMed ID: 4375206
    [No Abstract]   [Full Text] [Related]  

  • 7. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
    Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells.
    Asp V; Cantillana T; Bergman A; Brandt I
    Xenobiotica; 2010 Mar; 40(3):177-83. PubMed ID: 20044879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypouricemic effect of o,p'-DDD.
    Zumoff B
    Am J Med Sci; 1979; 278(2):145-7. PubMed ID: 517567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex.
    Pushkarev VM; Tronko ND; Kostyuchenko NN; Mikosha AS
    Ukr Biokhim Zh (1999); 2007; 79(2):44-9. PubMed ID: 18030749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic activation and binding of mitotane in adrenal cortex homogenates.
    Cai W; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    J Pharm Sci; 1995 Feb; 84(2):134-8. PubMed ID: 7738789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of mitotane (o,p'-DDD) in adrenal cortex hyperfunction].
    Kasperlik-Załuska A; Migdalska B
    Endokrynol Pol; 1982; 33(1-3):99-104. PubMed ID: 7183447
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosynthesis of various steroids in vitro by isolated adrenal cells in primary aldosteronism, Cushing's syndrome, and adrenogenital syndrome due to adrenocortical adenoma.
    Mizuno S; Funahashi H
    Nagoya J Med Sci; 1981 Nov; 44(1-2):11-22. PubMed ID: 7322196
    [No Abstract]   [Full Text] [Related]  

  • 15. [Corticosteroid synthesis in chicken adrenals as affected by o,p'-DDD].
    Kravchenko VI
    Ukr Biokhim Zh (1978); 1978; 50(2):180-3. PubMed ID: 307291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.
    Leiba S; Weinstein R; Shindel B; Lapidot M; Stern E; Levavi H; Rusecki Y; Abramovici A
    Ann Endocrinol (Paris); 1989; 50(1):49-53. PubMed ID: 2729882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACTH sensitivity of isolated human pathological adrenocortical cells: variability of responses in aldosterone, corticosterone, deoxycorticosterone and cortisol production.
    Rácz K; Varga I; Kiss R; Gláz E
    J Steroid Biochem; 1984 May; 20(5):1187-94. PubMed ID: 6328122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The response of corticotropin and adrenal steroids to desmopressin stimulation in patients with various forms of hypercortisolism.
    Marova EI; Goncharov NP; Kolesnikova GS; Arapova SD; Lapshina AM
    Hormones (Athens); 2008; 7(3):243-50. PubMed ID: 18694863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of plasma and urinary 17-hydroxycorticosteroid determinations in Cushing's syndrome.
    LINDSAY AE; MIGEON CJ; NUGENT CA; BROWN H
    Am J Med; 1956 Jan; 20(1):15-22. PubMed ID: 13282918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.